Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)

ELITE PHARMACEUTICALS INC /NV/

2026-Q2 EPS reported $0.01 revenue$76,532,801

Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.
Income from operations $8.2M, up $4.7M or 136% YoY.
Growth driven by lisdexamfetamine product launches and strong Elite label product lines.
Conference call scheduled for Monday, Nov 17, 2025 at 11:30 AM EST.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.